The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review.

Autor: van der Horst RL; Division Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, The Netherlands; Maastricht UMC+ Comprehensive Cancer Center, Maastricht, The Netherlands. Electronic address: ra.vanderhorst@zuyderland.nl., van der Hel O; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands., Lutgens L; GROW-School for Oncology and Reproduction, Maastricht University, The Netherlands; Department of Radiation Oncology, MAASTRO Clinic, Maastricht, The Netherlands; Maastricht UMC+ Comprehensive Cancer Center, Maastricht, The Netherlands., van der Aa M; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands., Slangen B; GROW-School for Oncology and Reproduction, Maastricht University, The Netherlands; Department of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, The Netherlands; Maastricht UMC+ Comprehensive Cancer Center, Maastricht, The Netherlands., Kruitwagen R; GROW-School for Oncology and Reproduction, Maastricht University, The Netherlands; Department of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, The Netherlands; Maastricht UMC+ Comprehensive Cancer Center, Maastricht, The Netherlands., Lalisang RI; Division Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, The Netherlands; Maastricht UMC+ Comprehensive Cancer Center, Maastricht, The Netherlands.
Jazyk: angličtina
Zdroj: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2022 Jul; Vol. 175, pp. 103701. Date of Electronic Publication: 2022 May 06.
DOI: 10.1016/j.critrevonc.2022.103701
Abstrakt: The uterine carcinosarcoma (UCS) is a rare entity with poor prognosis. Treatment of FIGO I-II UCS usually consists of surgery with or without adjuvant treatment. Due to the high metastatic potential, aggressive combined modality adjuvant treatment approaches, consisting of chemo- and radiotherapy, have been of interest. Our systematic review aims to compare survival, disease control and toxicity profiles in patients receiving adjuvant chemoradiation to other adjuvant strategies (e.g.observation, chemotherapy or radiotherapy). A total of ten studies were included for a combined cohort size of 6520 patients. Generally, the studies showed a trend towards improved disease control and survival in patients undergoing adjuvant multimodal treatment, although statistical significance was often not reached. Selection bias and non-randomized treatment allocation pose serious challenges to extrapolate these outcomes to clinical practice. We recommend additional prospective research on the role of adjuvant chemoradiation in FIGO I-II UCS.
(Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: